• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/30

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

30 Cards in this Set

  • Front
  • Back
ACTIVATED CHARCOAL
(CLASS/MOA)
C: ABSORBENT
MOA: ABSORBS TOXIC SUBSTANCES FROM THE GI TRACT. ONSET IS IMMEDIATE.
ACTIVATED CHARCOAL
(INDICATIONS/CONTRAINDICATIONS)
I: MOST ORAL POISONINGS AND MEDICATION OVERDOSES.
C: ORAL ADMINISTRATION TO A COMATOSE PT, S/P INGESTION OF CORROSIVES, CAUSTICS, OR PETROLEUM DISTILLATES. SIMULTANEOUS ADMINISTRATION WITH OTHER ORAL DRUGS.
ACTIVATED CHARCOAL
(DOSE/ADMINISTRATION)
*NOTE IF NOT PREMIXED, DILUTE WITH 1 PART CHARCOAL/4 PARTS WATER.
ADULT: 1-2gm/kg PO or via NGT
PEDI: 1-2gm/kg PO or via NGT
ACTIVATED CHARCOAL
(ADVERSE REACTIONS/HOW SUPPLIED)
AR: MAY INDUCE NAUSEA, VOMTING, CONSTIPATION, BLACK STOOLS.
HS: (200mg/ml)
25gm in 125ml bottle
50gm in 250ml bottle
ACTIVATED CHARCOAL
(DRUG INTERACTIONS/DURATION)
DI: BONDS WITH AND INACTIVATED GENERALLY WHATEVER IT IS MIXED WITH.
D: DEPENDS ON GI FUNCTION, WORKS UNTIL EXCRETED
ACTIVATED CHARCOAL
(SPECIAL CONSIDERATIONS)
DOES NOT ABSORB CYANIDE, LITHIUM, IRON, LEAD, AND ARSENIC
ADENOSINE
(CLASS/MOA)
C: ENDOGENOUS NUCLEOTIDE
MOA: SLOW CONDUCTION TIME THROUGH AV NODE, CAN INTERRUPT RE-ENTRANT PATHWAYS, SLOWS HEART RATE, ACTS DIRECTLY ON SINUS PACEMAKER CELLS, DRUG OF CHOICE FOR PSVT,
ADENOSINE
(INDICATIONS/CONTRAINDICATIONS)
I: COVERSION FROM PSVT TO SINUS RHYTHM, MAY CONVERT PSVT DUE TO WPW SYNDROME. NOT EFFECTIVE WITE AFIB/AFLUTTER
C: 2ND OR 3RD DEGREE HB
AFIB/AFLUTTER
VTACH
HYPERSENSITIVITY
ADENOSINE
(DOSE/ADMINISTRATION)
ADULT (IVP):
6mg over 1-3 seconds, if no response after 1-2 minutes, administer 12mg over 1-3 seconds, MAX DOSE: 30mg
PEDI:
0.1 - 0.2 mg/kg rapid IV, MAX SINGLE DOSE: 12mg
ADENOSINE
(ADVERSE REACTIONS/HOW SUPPLIED)
AR: FACIAL FLUSHING, SOB, CP, HA, PARESTHESIA, DIAPHORESIS, HYPOTENSION, NAUSEA, METALLIC TASTE
HS:
3mg/ml in 2ml flip-top vials for IV injection
ADENOSINE
(DRUG INTERACTIONS/DURATION)
DI: METHYLXANTHINES, DIPYRIDAMOLE, CARBAMAZEPINE, CAN CAUSE BRONCHOCONSTRICTION IN ASTHMA PTS.
ADENOSINE
(SPECIAL CONSIDERATIONS)
SHORT HALF LIFE
PREGNANCY: C
ALBUTEROL
(CLASS/MOA)
C: Sympathomimetic, bronchodilator.
MOA: Selective b-2 agonist which stimulates adrenergic receptors of the sympathomimetic
nervous system resulting in smooth muscle relaxation in the bronchial tree and
peripheral vasculature.
ALBUTEROL
(INDICATIONS/CONTRAINDICATIONS)
I: Treatment of bronchospasm in patients with reversible obstructive airway disease
(COPD/asthma). Prevention of exercise-induced bronchospasm.
C: Known prior hypersensitivity reactions to Albuterol.
Tachycardia dysrhythmias, especially those caused by digitalis.
Synergistic with other sympathomimetics
ALBUTEROL
(DOSE/ADMINISTRATION)
Adult: Administer 2.5 mg. Dilute 0.5 ml of 0.5% solution for inhalation with 2.5 ml
normal saline in nebulizer and administer over 10-15 minutes.
MDI: 1-2 inhalations (90-180 mcg). Five minutes between inhalations
Pediatric: Administer solution of 0.01 - 0.03 ml (0.05 - 0.15 mg/kg/ dose diluted in
2 ml of 0.9% Normal Saline. May repeat every 20 minutes three times.
ALBUTEROL
(ADVERSE REACTIONS/HOW SUPPLIED)
AR:Often dose-related and include restlessness, tremors, dizziness, palpitations,
tachycardia, nervousness, peripheral vasodilatation, nausea, vomiting, hyperglycemia,
increased blood pressure and paradoxical bronchospasm
HS:Solution for aerosolization: 0.5% (5 mg/ml)
Metered Dose Inhaler: 90 mcg/metered spray (17 gm canister with 200 inhalations)
Syrup: 2 mg/5 ml
ALBUTEROL
(DRUG INTERACTIONS/DURATION)
DI: Tricyclic antidepressants may potentate vasculature effects.
Beta-blockers are antagonistic.
May potentate hypokalemia caused by diuretics.
D:Onset in 5-15 minutes with peak effect in 30-minutes - two hours and duration of 3-4
hours.
ALBUTEROL
(SPECIAL CONSIDERATIONS)
Pregnancy Safety: Category C.
Antagonized by beta-blockers (e.g., Inderal, Metoprolol )
May precipitate angina pectoris and dysrhythmias.
Should only be administered by inhalation methodology in pre-hospital management.
AMIODARONE
(CLASS/MOA)
C: Antidysrhythmic
MOA: Prolongation of Action Potential; non-competitive alpha and beta sympathetic blocking
effects; Calcium channel blocking effects.
AMIODARONE
(INDICATIONS/CONTRAINDICATIONS)
I: Suppression of Ventricular Fibrillation refractory to defibrillation.
Suppression of Ventricular Tachycardia refractory to cardioversion.
C:Second or Third Degree heart block.
Medication-induced Ventricular dysrhythmias.
Hypotension, Bradycardia, Torsades de Pointes.
Profound Sinus Bradycardia
AMIODARONE
(DOSE/ADMINISTRATION)
Adult: 300 mg slow IV Push over 1-2 minutes in 10 ml Normal Saline, (For ACLS
VF/ Pulseless VT)
IV Drip 0.5-1mg per minute. (For malignant ventricular arrhythmias) per ordering
physician.
AMIODARONE
(ADVERSE REACTIONS/HOW SUPPLIED)
AR:Hypotension, Bradycardia, Pulseless Electrical Activity, Congestive Heart Failure.
Nausea, fever, abnormal Liver Function Tests, Thrombocytopenia.
HS:150 mg in 3 ml vials.
AMIODARONE
(DRUG INTERACTIONS/DURATION)
DI: Will precipitate with Sodium Bicarbonate: incompatible.
Compatible with: Dopamine, Dobutamine, Isoproterenol, Lidocaine, NTG,
Norepinephrine, Phenylephrine, KCL, Procainamide.
D:Onset: Within 5-15 minutes.
Peak Effect: Variable.
Duration: Variable
AMIODARONE
(SPECIAL CONSIDERATION)
Pregnancy safety: Category C
Maintain at room temperature and protect from light in storage (light protection not
required during administration).
Hypotension usually responsive to slowing infusion rate, IV Normal Saline.
Administer cautiously in patients with Heart Failure or poor systolic function.
May be especially effective in high-risk patients with recent acute MI.
ASPIRIN
(CLASS/MOA)
C: Platelet inhibitor, anti-inflammatory agent.
MOA: Prostaglandin inhibition.
ASPIRIN
(INDICATIONS/CONTRAINDICATIONS)
I: New onset chest pain suggestive of Acute Myocardial Infarction
C: Hypersensitivity.
Gastrointestinal bleeding.
ASPIRIN
(DOSE/ADMINISTRATION)
160 mg or 325 mg PO.
ASPIRIN
(ADVERSE REACTIONS/HOW SUPPLIED)
AR: Heartburn.
GI bleeding.
Nausea, vomiting.
Wheezing in allergic patients.
Prolonged bleeding.
HS:
160 mg or 325 mg tablets (chewable and standard)
ASPIRIN
(DRUG INTERACTIONS/DURATION)
DI: Use with caution in patients allergic to NSAIDS.
D: Onset: 30-45 minutes.
Peak effect: variable.
Duration: Variable.
ASPIRIN
(SPECIAL CONSIDERATIONS)
Pregnancy Safety: Category D.
Not recommended in pediatric population